Soligenix Receives Orphan Drug Designation for Dusquetide to Treat Behcet's Disease.

Soligenix, a biopharmaceutical company, has announced that its dusquetide treatment has received orphan drug designation from the US FDA to treat Behcet's disease. The designation is intended to encourage the development of treatments for rare diseases. Soligenix is focused on developing and commercializing products for rare diseases where there is an unmet medical need.

Soligenix, Inc. (NASDAQ: SNGX), a biopharmaceutical company focused on developing treatments for rare diseases, has announced that its dusquetide treatment has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Behçet's Disease. This designation, granted following promising Phase 2a clinical results, is intended to encourage the development of treatments for rare diseases and offers significant regulatory and financial benefits to Soligenix.

Behçet's Disease is a rare inflammatory disorder affecting approximately 18,000 people in the U.S. and up to 1 million worldwide. The condition causes painful mouth sores, skin rashes, genital sores, leg ulcers, and eye inflammation. The orphan drug designation provides Soligenix with seven years of market exclusivity upon potential FDA approval, allowing the company to access various financial and regulatory benefits, including government grants, FDA user fee waivers, and certain tax credits [1].

The designation follows Soligenix’s Phase 2a pilot study involving eight patients with Behçet’s Disease, which demonstrated a 40% improvement in oral ulcers after four weeks of treatment compared to placebo data [1]. The company’s President and CEO, Christopher J. Schaber, expressed optimism about dusquetide's potential to help underserved patients suffering from this difficult-to-treat and chronic autoimmune disease.

Unlike the only currently approved drug for Behçet’s Disease, apremilast (Otezla), which requires continuous administration and commonly causes side effects, Soligenix reported that SGX945 was well-tolerated with no treatment-related adverse events in its small study [1]. Dusquetide, classified as an innate defense regulator, modulates the body’s reaction to injury and infection, offering a novel approach to treating Behçet’s Disease.

This designation strengthens Soligenix's intellectual property position and regulatory pathway for SGX945, providing momentum for this program within their rare disease portfolio. The company now benefits from enhanced FDA interaction opportunities and a potentially streamlined approval process specifically designed for orphan drugs treating serious conditions with unmet needs [2].

Soligenix's recent achievements highlight the company's ongoing progress and challenges in its business operations and regulatory compliance. The company reported stockholders’ equity of $1,828,951, falling short of the $2.5 million required by Nasdaq Listing Rule 5550(b)(1). However, this figure does not account for approximately $1.44 million in gross proceeds from sales under its At-The-Market facility [1].

The orphan drug designation for dusquetide marks a significant milestone for Soligenix, positioning the company to potentially address a significant unmet medical need in Behçet’s Disease treatment. The designation provides substantial regulatory advantages and market exclusivity, boosting the company's position in this rare disease market [2].

References:
[1] https://www.investing.com/news/company-news/fda-grants-soligenix-orphan-drug-designation-for-behcets-disease-93CH-4197504
[2] https://www.stocktitan.net/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-the-treatment-of-1ha7eiwia524.html